• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Obstetrics

Exemestane for breast cancer prevention has little effect on quality of life

byMonica ParksandAndrew Bishara
April 11, 2014
in Obstetrics, Oncology, Uncategorized
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

Image: PD

1. Exemestane given for prevention of breast cancer in post-menopausal women has limited negative effects on menopause-specific and health-related quality of life.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Exemestane, a steroidal aromatase inhibitor, was shown in the Mammary Prevention 3 (MAP.3) trial  to reduce the risk of breast cancer among post-menopausal women when given prophylactically. The purpose of this follow-up study was to examine the effects of this regimen on quality of life among the patients during this trial. After collecting survey responses on both menopause-specific and overall quality of life measures from patients in both the exemestane and placebo arms, the authors found that differences were minimal. There were small negative effects on vasomotor and sexual symptoms and pain among women treated with exemestane. However, most of this difference was attributed to a small number of women in the treatment arm with clinically important declines in quality of life. Treatment discontinuation rates were also similar between the exemestane and placebo groups. It should be noted that, while these results are supported by high survey response rates and the randomized, controlled design of the original trial, these surveys were a secondary outcome.

Click to read the study in JCO

In-Depth [prospective randomized controlled trial]: The MAP.3 study was a randomized, placebo-controlled trial that enrolled a total of 4560 post-menopausal women assigned to either exemestane or placebo. In order to evaluate effects on quality of life, the study authorsused the four Menopause-Specific Quality of Life Questionnaire (MENQOL) domains and the eight Medical Outcomes Study Short Form Health Survey (SF-36). Responses were collected at baseline, then at 6 months, then annually. MENQOL response rates were high in both groups, ranging from 88% to 98%. At the conclusion of the trial, the authors found only small negative effects on self-reported vasomotor or sexual symptoms or pain. Most of these effects were attributed to a small number of patients in the exemestane arm with clinically important decline in quality of life. No other significant differences were found between the treatment and placebo arms. Overall, 32% of women in the exemestane arm and 28% of women in the placebo arm discontinued treatment.

RELATED REPORTS

Sacituzumab tirumotecan may have a role in the treatment of metastatic non-small cell lung cancer

2 Minute Medicine: Pharma Roundup – Perioperative Immunotherapy Efficacy, Expanded Prostate Cancer Indication, Rapid Subcutaneous Myeloma Administration, and Regulatory Compliance Findings [June 4 2025]

Physical disability and psychological distress demonstrate marked progression after diagnosis of cancer

More from this author: Rituximab linked with reduced chronic immune disease following stem cell transplantation, High-dose prophylaxis for hemophilia increases costs with minimal benefit, Ambrisentan found ineffective against idiopathic pulmonary fibrosis

©2012-2014 2minutemedicine.com. All rights reserved. No works may be reproduced without expressed written consent from 2minutemedicine.com. Disclaimer: We present factual information directly from peer reviewed medical journals. No post should be construed as medical advice and is not intended as such by the authors, editors, staff or by 2minutemedicine.com. PLEASE SEE A HEALTHCARE PROVIDER IN YOUR AREA IF YOU SEEK MEDICAL ADVICE OF ANY SORT.

Tags: Breast Cancerexemestaneoncologypost menopausal
Previous Post

Cetuximab and neoadjuvant chemotherapy may decrease survival in liver metastasis

Next Post

Increased incidence of stroke found after aortic valve replacement

RelatedReports

Lessons from real-world implementation of lung cancer screening
AI Roundup

Sacituzumab tirumotecan may have a role in the treatment of metastatic non-small cell lung cancer

June 10, 2025
2 Minute Medicine: Pharma Roundup: Price Hikes, Breakthrough Approvals, Legal Showdowns, Biotech Expansion, and Europe’s Pricing Debate [May 12nd, 2025]
Pharma

2 Minute Medicine: Pharma Roundup – Perioperative Immunotherapy Efficacy, Expanded Prostate Cancer Indication, Rapid Subcutaneous Myeloma Administration, and Regulatory Compliance Findings [June 4 2025]

June 4, 2025
AI Roundup

Physical disability and psychological distress demonstrate marked progression after diagnosis of cancer

May 28, 2025
Thrombophilia-associated stillbirth risk appears limited to factor V Leiden
Hematology

Reduced-dose apixaban noninferior to full dose for cancer-associated thrombosis

May 20, 2025
Next Post
Transcatheter aortic valve replacement provides only minor benefit to quality of life

Increased incidence of stroke found after aortic valve replacement

Clinic intervention reduces pregnancy risk behaviors in vulnerable youth

Low hCG in early pregnancy associated with preeclampsia

Retinopathy of prematurity associated with nonvisual impairment in childhood

TGF-β1 polymorphism may protect against diabetic retinopathy

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Transcatheter closure of patent ductus arteriosus demonstrates similar outcomes compared to surgical repair
  • #VisualAbstract: Encorafenib, Cetuximab, and mFOLFOX6 Improves Survival in BRAF-Mutated Colorectal Cancer
  • Use of psychiatric medications may be associated with a higher risk of amyotrophic lateral sclerosis
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.